Cost-utility of aripiprazole once-monthly versus paliperidone palmitate once-monthly injectable for schizophrenia in China.

ABSTRACT:

Objectives

From the perspective of Chinese healthcare system, this study compared the cost-utility of aripiprazole once-monthly (AOM) and paliperidone palmitate once-monthly injectable (PP1M) in the treatment of adult patients with schizophrenia in China.

Methods

A 5-state Markov model was developed to evaluate the cost-utility of 10 years of long-acting injections (LAI) treatment for schizophrenia. The long-term costs and quality-adjusted life years (QALYs) were estimated, with the incremental cost-effectiveness ratio (ICER) as the primary outcome. The annual discount rate was set at 5%. A cost-effectiveness threshold (CET) of 0.51 times China's 2023 gross domestic product (GDP) (US$ 6,394.536) was used to judge the economics of intervention.

Results

The current pric

SUBMITTER: An Y 

PROVIDER: S-EPMC12200646 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature